Hormonal
Tirzepatide (5-15 mg weekly) produces dose-dependent weight loss (up to 25.3%) by acting as a dual GLP-1 and GIP receptor agonist.
Tirzepatide is a weekly injectable medication that mimics two gut hormones (GLP-1 and GIP) to regulate appetite and metabolism. Clinical trials show it can lead to up to 25% body weight loss, significantly outperforming placebo. It requires a prescription and ongoing medical supervision, and discontinuation leads to weight regain.
Tirzepatide is the first polypeptide to act as both a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist... The results showed dose-dependent weight loss: an average reduction of 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg... Over the entire study period, the tirzepatide group achieved a total weight reduction of 25.3%...
Why this rating
Based on multiple large, randomized, double-blind, placebo-controlled trials (SURMOUNT-1, 2, 3, 4).
Source
TRENDS IN OBESITY TREATMENT: A REVIEW OF THE LITERATURE FROM THE LAST SIX YEARS
Adam Sobiński et al. · International Journal of Innovative Technologies in Social Science · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →